Financial Health Snapshot
What do Cigna Corporation’s latest financial health metrics show?
Strong overall. The strongest factor is earnings scale, while the main concern is cash-flow volatility.
Cigna Corporation’s latest verified period is Q1 2026, with support from FY2025 where relevant. The verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For background, Cigna Corporation (CI): History, Ownership, Mission, How It Works & Makes Money helps frame the business model behind these results.
Revenue growth deserves deeper analysis first because it best explains how the rest of the snapshot is holding up.
Revenue and Earnings Quality
Does Cigna revenue growth translate into higher-quality earnings?
Mixed. Revenue is growing, but the clearest confirmation is that adjusted income from operations and per-share earnings are also rising. The main divergence is mix: Cigna Healthcare is shrinking after the Medicare divestiture, while Evernorth Health Services is carrying more of the growth.
Investors care less about revenue alone and more about whether that growth turns into durable operating income, net income, and EPS across comparable annual periods. For Cigna Corporation, that means checking whether the stronger top line is being converted into real earnings power, not just higher reported sales. The mission and business mix also matter, and Mission Statement, Vision, & Core Values (2026) of Cigna Corporation (CI) helps frame that shift.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $2749B, up 110%, FY2025 Total Revenues | $34B, FY2024 Total Revenues | Unclear from the supplied data whether growth was organic, acquired, price-led, or volume-led | Repeatability is harder to judge because the mix changed and the reported revenue base expanded sharply |
| Operating Income | $80B, up 40%, FY2025 Adjusted Income from Operations | Not provided for FY2024 | Growth was slower than revenue | Margins appear to lag the top line, so revenue growth is not fully converting into operating leverage |
| Net Income | $60B, or $2218 per share, FY2025 Shareholders' Net Income | $34B, FY2024 Shareholders' Net Income | No unusual-item detail was supplied; the direction is positive | Final earnings improved, which supports the operating trend and suggests stronger earnings quality |
| Diluted EPS | $2984 per share, FY2025 Adjusted Income from Operations | Not provided for FY2024 | Per-share conversion strengthened, but share-count effects cannot be isolated from the supplied data | Shareholders saw better per-share earnings, which supports the business result |
How durable is Cigna Corporation’s revenue?
The strongest durability signal is scale in recurring health services, especially Evernorth Health Services. The biggest limitation is concentration and mix change, because Cigna Healthcare’s full-year 2025 adjusted revenues fell 110% after the Medicare divestiture.
- Demand Quality: Recurring health services support visibility, but the business mix is shifting, so durability is better than a one-time sales spike.
- Pricing and Volume: The split between price, volume, and mix was not fully provided, so the source of growth is only partly visible.
- Diversification: Evernorth grew to $1953B in adjusted revenues, while Cigna Healthcare fell to $472B, showing meaningful segment concentration change.
That mix shift matters because it can change profitability and cash conversion even when revenue keeps rising.
Profitability and cash
How strong are Cigna Corporation margins and cash conversion?
Cigna Corporation’s margins were mixed: the clearest supplied margin metric, Cigna Healthcare Medical Care Ratio, worsened to 84.4% for full-year 2025 from 83.2% in 2024, while Q1 2026 showed 79.8%. Cash conversion is weaker than reported earnings suggest because operating and free cash flow growth were both sharply negative in 2026-03-31.
Cigna Corporation still posted Q1 2026 Revenue of $68.49B, Gross Profit of $6.47B, Operating Income of $2.36B, and Net Income of $1.65B, but earnings quality needs a cash check. Interest Expense was $357.00M and Income Tax Expense was $409.00M, while special items and Strategic Optimization charges also weighed on the bottom line.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Cigna Healthcare Medical Care Ratio: 79.8% in Q1 2026 | Cigna Healthcare Medical Care Ratio: 84.4% in full-year 2025 | Higher costs in the Individual and Family Plans business | Lower medical cost pressure in the quarter, but the full-year pattern still shows a tight margin structure |
| Operating Margin | Operating Income of $2.36B in Q1 2026; margin not supplied | Operating margin not supplied | Special items of $322M after-tax charges and $380M in pre-tax Strategic Optimization Program charges, mainly severance | Profitability is still being affected by restructuring and portfolio actions |
| Net Margin | Net Income of $1.65B in Q1 2026; margin not supplied | Net margin not supplied | $357.00M interest expense, $409.00M income tax expense, and special charges | Bottom-line earnings are supported by operations, but they are diluted by financing, tax, and one-time items |
| Operating Cash Flow | Unavailable in supplied data for 2026-03-31 | Unavailable in supplied data | Operating Cash Flow Growth was -8161% for 2026-03-31 | Reported earnings are not converting cleanly into operating cash |
| Free Cash Flow | Unavailable in supplied data for 2026-03-31 | Unavailable in supplied data | Free Cash Flow Growth was -8517% for 2026-03-31; capex was not supplied | Less cash remains for reinvestment, debt reduction, and shareholder returns |
What most affects Cigna Corporation cash conversion?
The main drag is the sharp deterioration in cash flow growth, alongside restructuring charges and higher medical cost pressure; that looks partly temporary, but the supplied data do not prove when cash conversion will normalize.
- Main Driver: Negative operating and free cash flow growth, plus Strategic Optimization charges, suggest a mix of temporary restructuring and near-term cash pressure.
- Evidence Gap: The supplied data do not show operating cash flow, free cash flow, or capex dollar amounts.
- Metric to Monitor: Watch Cigna Healthcare Medical Care Ratio and operating cash flow next quarter.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For company background, see Cigna Corporation (CI): History, Ownership, Mission, How It Works & Makes Money.
Liquidity Check
Does Cigna have enough liquidity and balance sheet flexibility to support its obligations and investment needs?
Mixed. Cigna Corporation has strong cash liquidity, but leverage is a clear constraint because debt is high relative to cash. The main protection is $70B in cash and cash equivalents; the main financing concern is the large debt load and the need to preserve flexibility for capital returns and portfolio actions.
Cigna Corporation’s balance sheet needs to be read as a full system, not just a cash number. Cash helps with near-term funding, but investors also need to look at debt service, solvency, refinancing flexibility, and whether capital can still support dividends, share repurchases, integration, and post-divestiture actions.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | $70B in cash and cash equivalents at 2026-03-31. | Strong | Near-term liquidity looks solid, which helps Cigna Corporation meet obligations without immediate strain on investment spending. |
| Total and Net Debt | $3090B of total debt and $70B of cash at 2026-03-31. | Weak | Leverage is the main drag on flexibility, even with strong cash on hand. |
| Debt Service and Refinancing | Debt-to-capitalization ratio improved to 423% from 430% at December 31, 2025, and from 438% at year-end 2024; debt growth was -179% for 2026-03-31. | Mixed | The trend is better, but debt still absorbs financial capacity that could otherwise support capital returns and strategic moves. |
| Asset Quality | Recent supplied data does not include verified receivables, goodwill, intangibles, or impairment details. | Mixed | Asset-quality risk cannot be fully judged from the provided figures, so investors should focus on the debt trend and cash generation. |
| Liabilities and Equity | Latest verified total liabilities and shareholders' equity were not supplied in the prompt. | Mixed | The capital base cannot be fully measured here, but the lower debt trend still suggests improving flexibility after the $37B Medicare business divestiture. |
What balance-sheet risk matters most for Cigna Corporation?
Leverage is the key risk. Cigna Corporation’s cash position is strong, but the debt load and 423% debt-to-capitalization ratio are the main factors investors should watch.
- Current Exposure: $3090B of total debt versus $70B in cash at 2026-03-31.
- Protection: $70B in cash and cash equivalents plus an improving debt-to-capitalization ratio.
- Warning Signal: Watch whether leverage falls further or starts limiting dividends, share repurchases, and portfolio actions.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Cigna Corporation (CI): History, Ownership, Mission, How It Works & Makes Money can help you organize the research into clear arguments.
Capital efficiency
Is Cigna using capital efficiently after the portfolio changes?
Cigna Corporation looks Strong on capital efficiency. Internal cash appears sufficient for reinvestment needs, supported by heavy buybacks, a higher dividend, and a stated 2026 capital return plan, though actual ROIC, ROE, and ROA still need separate model inputs.
Return measures have to be read alongside leverage, asset intensity, capital spending, working capital, and any outside funding. For Cigna Corporation, the key evidence is not a published return ratio here, but how management is using cash after portfolio changes and whether those choices still leave room for reinvestment, including selective support such as CarepathRx in specialty pharmacy.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data; capital deployment evidence includes 119M shares repurchased for $36B in FY2025. | Buybacks suggest management has had excess capital, but operating margins and capital intensity still need a model-based ROIC check. | Investors can infer disciplined capital allocation, but not full value creation without an actual ROIC calculation. |
| ROE and ROA | FMP Weighted Average Shares Growth was -128% and Weighted Average Shares Diluted Growth was -065% for 2026-03-31. | Lower share counts can lift ROE mechanically, while ROA still depends on asset efficiency and profit generation. | Shareholder return quality looks supported by dilution control, but leverage and asset use still matter. |
| Maintenance and Growth Investment | The Board declared a quarterly cash dividend of $156 per share on February 05, 2026, up from $151 in 2025, and the company reiterated $16B in full-year 2026 shareholder dividends plus significant share repurchases. | Those actions show strong capital return capacity; CarepathRx shows selective reinvestment where specialty pharmacy growth still fits the portfolio. | Capital is being split between shareholder payouts and targeted growth, which usually signals a mature but still active reinvestment profile. |
| Internal Funding Capacity | The supplied evidence points to internal cash generation funding dividends, repurchases, and portfolio actions, with no outside capital need shown here. | If free cash flow stays strong and leverage remains disciplined, investment appears internally funded rather than dependent on external capital. | That supports flexibility, limits dilution, and usually helps preserve shareholder returns after portfolio changes. |
Are Cigna Corporation's returns on capital sustainable after the portfolio changes?
Likely yes, because cash generation and disciplined buybacks are the strongest support, but sustainability weakens if dividend growth, repurchases, or reinvestment needs outpace internal free cash flow.
- Operating Source: Share repurchases, a higher dividend, and selective portfolio actions suggest cash generation and capital discipline are supporting returns.
- Funding Requirement: The largest verified capital need is the $16B full-year 2026 shareholder dividend commitment, plus significant repurchases.
- Durability Test: Returns would weaken if free cash flow no longer covers dividends, buybacks, and reinvestment without added leverage or dilution.
Financial resilience
How resilient is Cigna Corporation, and which warning signs matter most?
Cigna Corporation looks Mixed. Its main buffer is the large Evernorth business and strong liquidity, but the most important verified warning sign is segment mix pressure after the Medicare divestiture and the 2025 membership drop, which can weaken revenue scale and operating leverage.
Cigna Corporation can still absorb stress because cash generation is supported by Evernorth, and the company reported $70 billion cash and a 423% Debt-to-Capitalization Ratio. That said, readers using Cigna Corporation (CI): History, Ownership, Mission, How It Works & Makes Money should watch whether health plan scale keeps shrinking and whether medical costs stay elevated enough to squeeze earnings and debt flexibility.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Cigna Healthcare full-year 2025 Adjusted Revenues fell 110% to $47.2B, mainly from the Medicare divestiture. Less scale can hurt operating leverage, earnings, cash flow, and debt capacity. | Evernorth Q1 2026 Adjusted Revenues of $58.4B and Q1 2026 pre-tax Adjusted Income of $1.5B help offset weakness. | Further decline in healthcare revenue, membership, or margin would confirm deterioration. |
| Working-Capital or Investment Pressure | Higher claims or restructuring needs can absorb cash that would otherwise fund operations, capex, or portfolio changes. | Internal cash generation and liquid balance sheet resources give Cigna Corporation some room to fund change without relying heavily on external financing. | Watch for weaker operating cash flow, rising medical claims, or larger special-item outflows. |
| Interest or Refinancing Pressure | Higher debt service would reduce free cash flow and limit flexibility if margins weaken further. | The 423% Debt-to-Capitalization Ratio and cash position suggest current leverage is manageable. | Rising debt, weaker coverage, or tighter liquidity would show refinancing pressure is building. |
Which financial warning signs should investors monitor at Cigna Corporation?
The top signals are membership trend, medical cost pressure, and restructuring charges. The first two are confirmed deterioration risks; the April 30, 2026 exit from the individual exchange business and the eviCore review are future scope risks to watch.
Membership loss after portfolio changes
Cigna Corporation’s Total Medical Customers were 183M in Q1 2026, up 16% year-over-year after the 2025 HCSC sale decline. If this stabilizes lower than expected, revenue scale and operating leverage can remain under pressure.
Medical cost inflation
The full-year 2025 Medical Care Ratio rose to 84.4% from 83.2% in 2024. If this keeps climbing, it can compress margins and reduce cash available for debt service and reinvestment.
Restructuring and portfolio exit costs
Cigna Corporation recorded $380M in pre-tax strategic optimization charges and $322M after-tax special items, or $1.22 per share. The planned exit from the individual exchange business at year-end 2026 and the eviCore review could add more transition costs.
Financial Health Scorecard
What does Cigna financial health mean for investors?
Cigna rates Mixed overall. The strongest factor is scale plus adjusted earnings, while the weakest factor is cash-flow and healthcare margin quality. The most important condition for the investment case is whether earnings stay strong enough to offset pressure in operating cash and medical costs.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | $2749B FY2025 Total Revenues, $685B Q1 2026 Total Revenues, and $206B Q1 2026 Adjusted Income from Operations show scale and earnings conversion that support per-share results. |
| Profitability and Cash | Mixed | Earnings are solid, but Medical Care Ratio pressure, $380M pre-tax charges, Operating Cash Flow Growth of -8161%, and Free Cash Flow Growth of -8517% weaken cash quality. |
| Balance Sheet and Liquidity | Strong | $70B Cash and Cash Equivalents support liquidity, even with a 423% Debt-to-Capitalization Ratio that keeps leverage and debt service important to watch. |
| Capital Efficiency | Strong | 119M shares repurchased for $36B in FY2025 and a $156 per share quarterly dividend show active capital return and limited dependence on new funding. |
| Financial Resilience | Mixed | Evernorth scale and leverage improvement help, but healthcare cost pressure and portfolio narrowing leave less room for error if margins weaken again. |
- What Supports the Thesis: Large revenue scale, strong adjusted operating income, and active share repurchases support earnings power.
- What Challenges the Thesis: Weak cash-flow growth and medical cost pressure raise doubt about earnings quality.
- What to Monitor: Cigna Healthcare Medical Care Ratio, Free Cash Flow Growth, Debt-to-Capitalization Ratio.
If you’re using this for a paper or case study, Mission Statement, Vision, & Core Values (2026) of Cigna Corporation (CI) can help connect financial health with strategy and operating priorities.
This scorecard should be tested against scenarios for medical cost trends, cash conversion, and leverage so forecasts and valuation assumptions reflect both earnings strength and balance-sheet pressure.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why is Cigna Healthcare's medical care ratio important?
It shows how much of premium revenue is used for medical costs Cigna Healthcare's full-year 2025 Medical Care Ratio was 844%, up from 832% in 2024, reflecting higher costs in the Individual and Family Plans business and making margin quality a key monitoring point
Does The Cigna Group generate enough cash for buybacks?
The company funded 119M share repurchases for $36B in FY2025 and reiterated significant share repurchases for 2026 However, Operating Cash Flow Growth of -8161% and Free Cash Flow Growth of -8517% for 2026-03-31 mean investors should monitor cash conversion
How much leverage does The Cigna Group carry now?
The Debt-to-Capitalization Ratio was 423% at March 31, 2026, down 70 basis points from December 31, 2025 That followed 430% at year-end 2025 and 438% at year-end 2024, showing gradual leverage improvement
What do restructuring charges mean for resilience?
The $380M pre-tax strategic optimization charges and $322M after-tax special items, or $122 per share, reduce reported quality in the period They also show that management is spending to narrow scope, adjust costs, and reposition the business after portfolio actions
How did the Medicare divestiture change financial health?
The $37B Medicare business sale narrowed Cigna Healthcare and contributed to a 50% membership decline in 2025 It also left Evernorth providing pharmacy benefit services to the divested Medicare businesses for an agreed post-closing period, preserving some service linkage